首页> 外国专利> HUMAN MONOCLONAL ANTIBODY BINDING THE ANTIGEN-4 OF CYTOTOXIC T-LYMPHOCYTE (CTLA-4), NUCLEIC ACID, CELL LINE, METHOD OF OBTAINING TRANSGENIC MAMMAL, METHOD TO INCREASE PRODUCING IL-2 OR IFN-? IN THE T-CELLS OF A PATIENT, METHOD TO TREAT AND PHARMACEUTICAL COMPOSITION USED IN TREATMENT OF CANCER, INFLAMMATION OR AUTOIMMUNE DISEASE, INCLUDING THE ANTIBODY

HUMAN MONOCLONAL ANTIBODY BINDING THE ANTIGEN-4 OF CYTOTOXIC T-LYMPHOCYTE (CTLA-4), NUCLEIC ACID, CELL LINE, METHOD OF OBTAINING TRANSGENIC MAMMAL, METHOD TO INCREASE PRODUCING IL-2 OR IFN-? IN THE T-CELLS OF A PATIENT, METHOD TO TREAT AND PHARMACEUTICAL COMPOSITION USED IN TREATMENT OF CANCER, INFLAMMATION OR AUTOIMMUNE DISEASE, INCLUDING THE ANTIBODY

机译：结合细胞毒性T淋巴细胞（CTLA-4）抗原4的人类单克隆抗体，核酸，细胞系，获得转基因哺乳动物的方法，增加产生IL-2或IFN-γ的方法在患者的T细胞中，用于治疗癌症，发炎或自身免疫性疾病的方法和药物组合物，包括抗体

页面导航

摘要
著录项
相似文献

摘要

The present invention relates to methods and products for immunotherapy resulting in the stimulation of T-cell proliferation. The products of the invention are peptides that bind to CTLA-4 and co-stimulate the proliferation of T-cells by inhibiting the binding of B7 to CTLA-4. Pharmaceutical compositions including such peptides are also provided. The invention further provides in vitro and in vivo therapeutic methods employing the peptides of theinvention.

机译：本发明涉及导致T细胞增殖的免疫疗法的方法和产品。本发明的产物是与CTLA-4结合并通过抑制B7与CTLA-4的结合而共同刺激T细胞增殖的肽。还提供了包括此类肽的药物组合物。本发明进一步提供了采用本发明的肽的体外和体内治疗方法。

著录项

公开/公告号UA76936C2

专利类型
公开/公告日2001-10-15

原文格式PDF
申请/专利权人 PFIZER INC.;ABGENIX INC.;
展开▼

申请/专利号UA20010075213
发明设计人
展开▼

申请日1999-12-23
分类号A01H5;A01K67/027;A61K39/395;A61P29;A61P35;A61P37/02;A61P37/04;C07K16;C07K16/28;C12N1/15;C12N1/19;C12N1/21;C12N5/10;C12N15/02;C12N15/09;C12P21/08;C12Q1/02;G01N33/15;G01N33/50;G01N33/577;
国家 UA
入库时间 2022-08-22 01:23:45

相似文献

专利
外文文献